- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01225198
Vitamin/Mineral Supplement for Children and Adults With Autism
October 19, 2010 updated by: Arizona State University
New Vitamin/Mineral Supplement for Children and Adults With Autism - National Study
The investigators hypothesis is that a new, revised formulation of a vitamin/mineral supplement will result in:
- improvement of nutritional status in some children/adults with autism, and
- reduction of some of the symptoms of autism in some children
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The major goal of this study is to determine the effect of this vitamin/mineral supplement on levels of vitamins, minerals, neurotransmitters, and biomarkers for nutritional deficiencies.
The study design is a randomized, double-blind, placebo-controlled.
Blood and urine measurements will be measured at the beginning of the study in children with autism and typical children.
Then, the children with autism will be given the supplement or placebo for 12 weeks, and then their blood and urine will be re-measured.
Study Type
Interventional
Enrollment (Actual)
143
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States, 85287
- Arizona State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 months to 56 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 3-60 years old;
- Autism Group: diagnosis of autism, pervasive developmental disorder/not otherwise specified (PDD/NOS), or Asperger's by a psychiatrist or similar professional
- Control Group: in good mental and physical health, and no siblings with autism spectrum disorders, and no evidence of Attention Deficit Disorder by parent report
Exclusion Criteria:
- Usage of a vitamin/mineral supplement in the last 2 months
- Current use of any chelation treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Group
Liquid placebo with identical packaging and flavoring to the real supplement.
|
The placebo was formulated to look and taste like the intervention supplement.
A small amount of beta-carotene was used for coloring.
Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste.
Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
|
|
Experimental: Vitamin/Mineral Supplement Group
Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
|
A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxidative Stress
Time Frame: Beginning of study (day 0)
|
Level of Plasma Nitrotyrosine
|
Beginning of study (day 0)
|
|
Oxidative Stress
Time Frame: End of Study (after 12 weeks of treatment)
|
Level of plasma nitrotyrosine
|
End of Study (after 12 weeks of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Parent Global Impressions - Revised
Time Frame: End of study (12 weeks)
|
The Average Change of the Parent Global Impressions (PGI-R) assessment tool.
|
End of study (12 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
September 14, 2010
First Submitted That Met QC Criteria
October 19, 2010
First Posted (Estimate)
October 20, 2010
Study Record Updates
Last Update Posted (Estimate)
October 20, 2010
Last Update Submitted That Met QC Criteria
October 19, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AutismVitaminStudy2008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Istituto Clinico HumanitasRecruitingAutism | Autism Spectrum Disorder (ASD) | Autism DisorderItaly
-
Istituto per la Ricerca e l'Innovazione BiomedicaRecruitingAutism | Autism DisorderItaly
-
University of NottinghamUniversity Hospitals of Derby and Burton NHS Foundation Trust; Lincolnshire...Not yet recruitingAutism Spectrum Disorder | Autism | Parent | Autism Disorder | Autism in Children | Parent Stress | Parent Mental Health | Autism Disorders and Maternal Stress | Parent SupportUnited Kingdom
-
Boston Children's HospitalRecruitingAutism Spectrum Disorder | Autism | Autism DisorderUnited States
-
The Children's Hospital of Zhejiang University...Not yet recruitingAutism | Autism Spectrum Disorder (ASD)China
-
Poznan University of Physical EducationCompletedAutism | Autism Spectrum Disorder (ASD)Poland
-
Greater Atlanta Integrative PediatricsRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Adia Med of Winter Park LLCRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Stanford UniversityJohn and Marcia Goldman FoundationNot yet recruitingAutism | Autism Spectrum Disorder (ASD)United States
-
Father Flanagan's Boys' HomeNational Institute on Deafness and Other Communication Disorders (NIDCD)Not yet recruitingAutism Spectrum Disorder | Autism | Autism, Susceptibility to, 6United States
Clinical Trials on Liquid Placebo
-
Bichedam Co., Ltd.RecruitingEssential HypertensionSouth Korea
-
VIVEX Biologics, Inc.MCRAWithdrawnOsteoarthritis, Knee
-
Materia Medica HoldingCompletedAcute Upper Respiratory InfectionsRussian Federation
-
Emerald Health PharmaceuticalsCompleted
-
Prof. Dominique de Quervain, MDCompleted
-
University of LeedsUnknown
-
Engelhard Arzneimittel GmbH & Co.KGCompleted
-
Anavex Life Sciences Corp.Anavex Australia Pty Ltd.; Anavex Germany GmbHCompletedRett SyndromeCanada, Australia, United Kingdom
-
Rigshospitalet, DenmarkUniversity of Texas Southwestern Medical Center; Groupe Hospitalier Pitie-Salpetriere and other collaboratorsCompletedGlycogen Storage Disease Type VDenmark
-
American University of Beirut Medical CenterNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedNicotine Dependence | Nicotine Vaping | Nicotine AddictionLebanon